167 related articles for article (PubMed ID: 38280040)
1. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract][Full Text] [Related]
2. Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.
Cedrés S; Montero MA; Zamora E; Martínez A; Martínez P; Fariñas L; Navarro A; Torrejon D; Gabaldon A; Ramon Y Cajal S; Felip E
Clin Transl Oncol; 2014 Sep; 16(9):776-82. PubMed ID: 24323466
[TBL] [Abstract][Full Text] [Related]
3. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
[TBL] [Abstract][Full Text] [Related]
4. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
5. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
6. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
8. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
9. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
10. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
11. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
12. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
13. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Kumar N; Alrifai D; Kolluri KK; Sage EK; Ishii Y; Guppy N; Borg E; Falzon M; Nankivell M; Nicholson AG; Janes SM
Lung Cancer; 2019 Jan; 127():164-166. PubMed ID: 30642545
[TBL] [Abstract][Full Text] [Related]
14. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
Cantini L; Pecci F; Murrone A; Tomasetti M; Copparoni C; Fiordoliva I; Morgese F; Rinaldi S; Mazzanti P; Rubini C; Cimadamore A; Barbisan F; Giampieri R; Scarpelli M; Santarelli L; Berardi R
Lung Cancer; 2020 Aug; 146():318-326. PubMed ID: 32622302
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
[TBL] [Abstract][Full Text] [Related]
16. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
17. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
18. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
[TBL] [Abstract][Full Text] [Related]
20. The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
Chou A; Toon CW; Clarkson A; Sheen A; Sioson L; Gill AJ
Histopathology; 2018 Feb; 72(3):509-515. PubMed ID: 28889523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
